1.
Strober B, Gottlieb A, Tha?i D, Puig L, Colombo MJ, Kundu S, Kisa R, Banerjee S. An Oral, Selective Tyrosine Kinase 2 Inhibitor, BMS-986165, Reduced Absolute Psoriasis Area and Severity Index in a Phase 2 Trial in Psoriasis. J of Skin [Internet]. 2020Sep.2 [cited 2022Jul.5];4(5):s27. Available from: https://www.jofskin.org/index.php/skin/article/view/976